Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xofigo (Radium 223 Dichloride),XofigoStudy001,2021,USA,MDV,350,72,2,98,27.5,60,75,85,5,15,40,40,30,40,20,10,2,8,20,20,10,5,12,8,5,15,25,Docetaxel,Carboplatin,Abiraterone,Enzalutamide,0,0,0,30,40,50,10,40,50,60,18
Xofigo (Radium 223 Dichloride),XofigoStudy002,2022,UK,Claim Database,420,75,3,97,28.0,55,70,80,7,13,35,45,35,35,20,10,3,7,18,22,12,6,14,9,7,17,27,Docetaxel,Cisplatin,Abiraterone,Enzalutamide,0,0,0,32,42,52,12,42,46,62,20
Xofigo (Radium 223 Dichloride),XofigoStudy003,2023,Canada,MDV,280,70,1,99,26.8,50,80,90,3,17,42,38,28,42,22,8,1,9,22,18,8,4,10,7,3,13,23,Docetaxel,Carboplatin,Abiraterone,Enzalutamide,0,0,0,28,38,48,8,38,54,58,16
Xofigo (Radium 223 Dichloride),XofigoStudy004,2024,Germany,Claim Database,480,73,4,96,27.2,58,73,83,6,14,37,43,33,37,18,12,2,8,19,21,11,5,13,8,6,16,26,Docetaxel,Cisplatin,Abiraterone,Enzalutamide,0,0,0,31,41,51,11,41,48,61,19
